ClinicalTrials.gg
CompletedNCT00387023Updated Nov 18, 2013Results posted

Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma

An interventional study of Rituximab and Zevalin in Non-Hodgkin's Lymphoma and Lymphoma, sponsored by M.D. Anderson Cancer Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-18.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing ibritumomab tiuxetan in Lymphoma, Non-Hodgkin — none open to participants now, none under way, none of them phase 3. ibritumomab tiuxetan · Lymphoma, Non-Hodgkin.

Enrollment
15th of 17
12 · median 28
Started
2004
with 1 other
No phase
Only one
of the 18
Registered
8th of 18
by date
Lead sponsor
2 of 18
M.D. Anderson Cancer Center

Among the 18 studies testing ibritumomab tiuxetan in Lymphoma, Non-Hodgkin, this one is the 15th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2004, is the only one with no phase, and was the 8th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

None of the 18 studies testing ibritumomab tiuxetan in Lymphoma, Non-Hodgkin is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →

About ibritumomab tiuxetan

ibritumomab tiuxetan: first FDA approval 2002 (ZEVALIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing ibritumomab tiuxetan in Lymphoma, Non-Hodgkin as a file.
02

Study summary

Primary Objectives:

  1. To evaluate the efficacy of Zevalin for the treatment of low-grade follicular Non-Hodgkin's lymphoma of the orbit or mucosa-associated lymphoid tissue (MALT) of conjunctiva using radiographic imaging, clinical examination (slit lamp biomicroscopy and external examination of the conjunctiva), and external photography whenever possible.
  2. To establish the safety profile in this patient population using clinical examination including slit lamp biomicroscopy, and evaluation of the tear film with Schirmer's test.
  3. To establish the dosimetry for Zevalin in the orbit in the first 3 patients who agree to undergo dosimetry.
Read the detailed description

Rituximab and Zevalin are monoclonal antibodies that bind to lymphoma cells and cause cell death.

As is the case for all patients with orbital lymphoma, an orbital biopsy must be performed to confirm the diagnosis and status of the orbital lymphoma. The study doctors must first make sure that the disease has not spread too much and is not severe enough to require immediate treatment with chemotherapy before you can begin treatment on this study. You will have about 4 teaspoons of blood drawn. Women who are able to have children must have a negative blood or urine pregnancy test.

You will receive two injections of rituximab by vein over about 4 to 6 hours. This is followed by an infusion of Zevalin over about 30 minutes on the same day. Whole body images will be performed immediately and at 4-6, 24, 72, and 144 hours after receiving Zevalin. About 1 week later, you will receive a second infusion of rituximab and Zevalin.

You may be taken off the study if your orbital lymphoma does not respond within three months of receiving rituximab and Zevalin. Researchers will measure your response to therapy using magnetic Resonance imaging (MRI) of the orbit and an evaluation of the eye in the clinic. If you are taken off study, you will be given the option of receiving external beam radiation therapy as treatment for the disease.

Follow-up evaluations will be done every 3 months for 2 years and every 6 months for Years 3 and 4. This testing is considered standard of care and would include medical history, physical exam, blood tests, and urine tests. The status of the disease will be evaluated using CT scan or MRI of the orbit every 3 months for the first year and every 6 months for Years 2, 3, and 4. Blood tests (about 4 teaspoons each) will be every 3 months for the first year and may be continues every 3 to 6 month until they become negative or you start another anti-cancer therapy.

This is an investigational study. Zevalin and rituximab are both FDA approved but their use together in this study is investigational. A total of up to 12 patients will take part in this study. All will be enrolled at The University of Texas (UT) MD Anderson Cancer Center.

03

Conditions studied

  • Non-Hodgkin's Lymphoma
  • Lymphoma

Keywords

  • Non-Hodgkin's Lymphoma
  • Orbital Lymphoma
  • Rituximab
  • Rituxan
  • Zevalin
  • Ibritumomab tiuxetan
  • IDEC-Y2B8
  • Eye
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. -proven diagnosis of low-grade Non-Hodgkin's follicular lymphoma of the orbit or MALT of the conjunctiva/orbit. The orbit/conjunctiva has to be the primary or predominant site of involvement or if there is a previous history of systemic involvement, the orbit/conjunctiva should be the only site of new recurrence.
  2. No anti-cancer therapy for three weeks (six weeks if Rituximab, nitrosourea or Mitomycin C) prior to study initiation, and fully recovered from all toxicities associated with prior surgery, radiation treatments, chemotherapy, or immunotherapy
  3. An Institutional Review Board (IRB)-approved signed
  4. Age >18 years. This is justified since low-grade non-Hodgkin's lymphoma of the orbit is extremely rare to non-existent in the pediatric population
  5. Expected survival of >3 months
  6. Pre-study performance status of 0, 1, or 2 according to the WHO
  7. Acceptable hematologic status within two weeks prior to patient registration, including: a) ([segmented neutrophils + bands] x total WBC)> 1500/mm3 b) Total lymphocyte count \< 5,000/mm3 for patients with small lymphocytic lymphoma (IWFA) c) counts> 150,000/mm3, these patients will receive a dose of 0.4 mCi/kg of Zevalin d) Platelet counts from 100,00/mm3 to 149,000/mm3, these patients will receive a 0.3mCi/kg dose of Zevalin
  8. Female patients who are not pregnant or lactating
  9. Men and women of who are following accepted methods (as determined by the treating physician, however abstinence is not an acceptable method)
  10. Patients previously on Phase II drugs are eligible if no long-term toxicity is expected, and the patient has been off the drug for eight or more weeks with no significant post treatment toxicities observed
  11. Patients determined to have less than 25% bone marrow involvement with lymphoma within six weeks of registration (based on a bone marrow biopsy). (This criteria must be strictly met for adequate patient safety.)

Exclusion criteria

Exclusion Criteria:

  1. Patients with impaired bone marrow reserve, as indicated by one or more of the following: a) Prior myeloablative therapies with bone marrow transplantation (ABMT) or peripheral blood stem cell (PBSC) rescue b) count \< than 100,000 cells/mm3 c) Hypocellular bone marrow (less than 15% cellularity) d) Marked reduction in bone marrow precursors of one or more cell lines (granulocytic, megakaryocytic, erythroid)
  2. Prior radioimmunotherapy
  3. Presence of central nervous system (CNS) lymphoma
  4. Patients with or AIDS-related lymphoma
  5. Patients with small lymphocytic lymphoma (IWF A) - who have a total lymphocyte count > 5,000/mm3
  6. Patients with pleural effusion
  7. Patients with abnormal liver function: total > 2.0 mg/dL
  8. Patients with abnormal renal function: serum creatinine > 2.0 mg/dL
  9. Patients who have received prior external beam radiation therapy to > 25% of active bone marrow (involved field or regional)
  10. Patients who have received Granulocyte colony-stimulating factor (G-CSF or GM-CSF) therapy within two weeks prior to treatment
  11. Serious nonmalignant disease or infection which, in the opinion of the investigator and/or the sponsor, would compromise other protocol objectives
  12. Major surgery, other than diagnostic surgery, within four weeks
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Zevalin + Rituximab

    Rituximab 250 mg/m\^2 intravenous (IV) over 4-6 hours for 2 weeks, + Zevalin 5 millicurie (mCi)/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.

    Drug: Rituximab · Drug: Zevalin

Interventions

  • 250 mg/m\^2 IV over 4-6 hours for 2 weeks.

    Also known as: Rituxan

  • DrugIbritumomab tiuxetanStudies of Ibritumomab tiuxetanIbritumomab tiuxetan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    5 mCi/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.

    Also known as: Ibritumomab tiuxetan, IDEC-Y2B8

06

What researchers measure

Primary outcomes

  1. Number of Participants With Complete Response (CR) or Partial Response (PR)

    Tumor response to therapy measured by tumor size as measured radiographically at baseline and at three months from baseline. Tumor response classified as complete response (CR) or partial response (PR), or stable disease (SD), or progressive disease (PD) using International Workshop Standardized Response Criteria (IWC) for Non-Hodgkin's Lymphomas. If the orbital/ocular adnexal lymphoma was not evaluable radiographically, clinical evaluation using slit lamp biomicroscopy was used to assess PR or CR.

    Time frame: 3 months

07

Results

Posted Nov 18, 2013

Participant flow

All recruitment done at The University of Texas (UT) MD Anderson Cancer Center between August 2004 and November 2007.

Participant flow — Overall Study
MilestoneZevalin + Rituximab
Started12
Completed12
Not completed0

Outcome measures

PrimaryNumber of Participants With Complete Response (CR) or Partial Response (PR)

Tumor response to therapy measured by tumor size as measured radiographically at baseline and at three months from baseline. Tumor response classified as complete response (CR) or partial response (PR), or stable disease (SD), or progressive disease (PD) using International Workshop Standardized Response Criteria (IWC) for Non-Hodgkin's Lymphomas. If the orbital/ocular adnexal lymphoma was not evaluable radiographically, clinical evaluation using slit lamp biomicroscopy was used to assess PR or CR.

Time frame:
3 months
Reported as:
Number · participants
Number of Participants With Complete Response (CR) or Partial Response (PR)
participantsZevalin + Rituximab
CR10
PR2

Adverse events

Collected over 7 years and 2 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zevalin + Rituximab—0/12 (0%)12/12 (100%)
Most frequent other events
Most frequent other events
EventZevalin + Rituximab
Transient PancytopeniaBlood and lymphatic system disorders12/12
FatigueGeneral disorders8/12
Increased BruisabilityGeneral disorders7/12
Joint and Muscle PainMusculoskeletal and connective tissue disorders4/12
NauseaGastrointestinal disorders3/12
HeadacheGeneral disorders3/12
AnemiaBlood and lymphatic system disorders1/12
FeverInfections and infestations1/12
DizzinessGeneral disorders1/12
FlushingSkin and subcutaneous tissue disorders1/12

Baseline characteristics

Age Continuous
Age Continuous(years)Zevalin + Rituximab
Median60 (22 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)Zevalin + Rituximab
Female7
Male5
Region of Enrollment
Region of Enrollment(participants)Zevalin + Rituximab
United States12
08

Study locations

1 site
  • UT MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2004, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2006
First posted
Oct 12, 2006
Start
Feb 2004
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Nov 18, 2013
Last update
Nov 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00387023
Collaborators
Biogen
Responsible party
Sponsor
First posted
Oct 12, 2006
Start date
Feb 2004
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Nov 18, 2013
Last update
Nov 18, 2013

Study contacts

Bita Esmaeli, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibritumomab tiuxetan

Start the discussion